Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series

被引：2
|
作者：
Nikanjam, Mina [1 ]
Mullen, Jaren [1 ]
Yacoub, Carol [2 ]
Daniels, Gregory A. [1 ]
机构：
[1] Univ Calif San Diego, Div Hematol Oncol, 3855 Hlth Sci Dr 0987, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Moores Canc Ctr Clin Pharm, 3855 Hlth Sci Dr 0987, La Jolla, CA 92093 USA
来源：
JOURNAL OF MEDICAL CASE REPORTS | 2022年 / 16卷 / 01期
关键词：
Interleukin-2; Anti-PD-1; Metastatic melanoma; Case report; THERAPY;
D O I：
10.1186/s13256-022-03536-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background Therapeutic options are needed for metastatic melanoma refractory to therapies directed against programmed cell death-1. High-dose interleukin-2 has the potential to overcome programmed cell death-1 resistance. Case presentation We report three consecutive Caucasian patients, two female (60 and 55 years old) and one male (56 years old), refractory to anti-programmed cell death-1 therapy who were treated with concurrent nivolumab and standard-dosing bolus high-dose interleukin-2. We did not see any unexpected toxicities with overlapping treatments as compared with either high-dose interleukin-2 or nivolumab alone. Conclusions The tolerance and disease control observed among the three patients in this limited series support formal exploration of this combination.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
    Buchbinder, Elizabeth I.
    Gunturi, Anasuya
    Perritt, Jessica
    Dutcher, Janice
    Aung, Sandra
    Kaufman, Howard L.
    Ernstoff, Marc S.
    Miletello, Girald P.
    Curti, Brendan D.
    Daniels, Gregory A.
    Patel, Sapna P.
    Kirkwood, John M.
    Hallmeyer, Sigrun
    Clark, Joseph I.
    Gonzalez, Rene
    Richart, John M.
    Lutzky, Joe
    Morse, Michael A.
    Sullivan, Ryan J.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [42] Experience in administration of high-dose interleukin-2 immunotherapy in combination with chemotherapy for disseminated skin melanoma management
    Baranau, Y.
    Zhavrid, E.
    Petrovitch, S.
    Sachivko, N.
    Zhuravkin, I.
    EJC SUPPLEMENTS, 2009, 7 (02): : 588 - 588
  • [43] The experience of administration of high-dose recombinant interleukin-2 in combination with chemotherapy in the management of disseminated skin melanoma
    Streltsova, Olga
    Baranau, Yauheni Valerievich
    Javrid, Edvard
    Barmotska, Maxim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Mixed Responder Cohort of Metastatic Melanoma Patients Treated with Anti Programmed Cell Death-1
    Cohen, S.
    Cintolo-Gonzalez, J.
    Plana, D.
    Sullivan, R.
    Boland, G. M.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S133 - S134
  • [45] TREATMENT OF 283 CONSECUTIVE PATIENTS WITH METASTATIC MELANOMA OR RENAL-CELL CANCER USING HIGH-DOSE BOLUS INTERLEUKIN-2
    ROSENBERG, SA
    YANG, JC
    TOPALIAN, SL
    SCHWARTZENTRUBER, DJ
    WEBER, JS
    PARKINSON, DR
    SEIPP, CA
    EINHORN, JH
    WHITE, DE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (12): : 907 - 913
  • [46] Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: Final data
    Ridolfi, L.
    Bulgarelli, J.
    Petracci, E.
    Pancisi, E.
    Piccinini, C.
    Granato, A.
    Petrini, M.
    Tazzari, M.
    Ancarani, V.
    Turci, L.
    Gentili, G.
    Valmorri, L.
    Romeo, A.
    De Giorgi, U. F. F.
    Burgio, S. L.
    Casadei, C.
    Cortesi, P.
    Lolli, C.
    De Rosa, F.
    Guidoboni, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
    Bulgarelli, Jenny
    Piccinini, Claudia
    Petracci, Elisabetta
    Pancisi, Elena
    Granato, Anna Maria
    de Rosa, Francesco
    Guidoboni, Massimo
    Petrini, Massimiliano
    Ancarani, Valentina
    Foschi, Giovanni
    Romeo, Antonino
    Tontini, Luca
    De Giorgi, Ugo
    Lolli, Cristian
    Gentili, Giorgia
    Valmorri, Linda
    Rossi, Alice
    Ferroni, Fabio
    Casadei, Carla
    Cortesi, Pietro
    Crudi, Laura
    Ridolfi, Laura
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [48] High-dose bolus interleukin-2 in elderly patients (>60 years old) with metastatic melanoma or renal cell cancer
    Homsi, J.
    Kim, L. C.
    Goetz, D.
    Chen, D.
    Fishman, M.
    Daud, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] High-dose recombinant interleukin-2/verapamil combination in advanced cancer
    Tagliaferri, P
    Correale, P
    Mottola, M
    deSimone, G
    Montesarchio, V
    Matano, E
    Rea, A
    Morabito, A
    Famiani, M
    Ciardiello, F
    Tortora, G
    Caraglia, M
    Barile, C
    Palmieri, G
    Bianco, AR
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (08) : 1436 - 1437
  • [50] CARDIOPULMONARY TOXICITY OF TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 IN 199 CONSECUTIVE PATIENTS WITH METASTATIC MELANOMA OR RENAL-CELL CARCINOMA
    WHITE, RL
    SCHWARTZENTRUBER, DJ
    GULERIA, A
    MACFARLANE, MP
    WHITE, DE
    TUCKER, E
    ROSENBERG, SA
    CANCER, 1994, 74 (12) : 3212 - 3222
12345